1800-272-662
Shopping Cart 0
countryflagAU
Login

Argent Biopharma Ltd

Healthcare AU RGT

0.043AUD
-0.001(2.27%)

Last update at 2026-03-13T05:10:00Z

Day Range

0.040.04
LowHigh

52 Week Range

0.040.27
LowHigh

Fundamentals

  • Previous Close 0.04
  • Market Cap3.78M
  • Volume83919
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-9.81953M
  • Revenue TTM0.35M
  • Revenue Per Share TTM0.005
  • Gross Profit TTM -0.63709M
  • Diluted EPS TTM-0.11

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -17.84429M -17.54843M -21.13152M -20.76782M -16.40650M
Minority interest - 0.02M 0.31M 0.37M -0.00865M
Net income -17.84429M -17.53060M -20.82358M -20.34744M -15.86998M
Selling general administrative 8.03M 8.67M 13.86M 10.82M 7.22M
Selling and marketing expenses 0.02M 2.42M 0.93M 1.01M 0.57M
Gross profit 0.45M 0.20M 0.70M 1.56M 0.74M
Reconciled depreciation 0.79M 1.29M 0.49M 0.50M 0.49M
Ebit -17.79299M -17.06596M -15.49329M -12.90359M -10.28213M
Ebitda -17.00385M -15.77216M -14.74135M -12.49837M -9.63934M
Depreciation and amortization 0.79M 1.29M 0.75M 0.41M 0.64M
Non operating income net other - - - - -
Operating income -15.44290M -18.26182M -15.49329M -12.90359M -10.28213M
Other operating expenses 16.03M 19.15M 18.88M 17.64M 13.28M
Interest expense 0.05M 0.48M 0.26M 0.21M 0.37M
Tax provision 0.00000M 0.00000M 0.00202M 0.00000M -0.02728M
Interest income 0.00224M 0.00193M 0.34M 0.00030M 0.36M
Net interest income -0.04906M -0.48054M -0.33701M -0.18975M -0.36150M
Extraordinary items - - - - -0.46264M
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 0.00202M -0.42039M -0.53453M
Total revenue 0.58M 0.89M 3.39M 4.73M 3.00M
Total operating expenses 15.89M 18.47M 16.19M 14.47M 11.02M
Cost of revenue 0.14M 0.69M 2.69M 3.17M 2.26M
Total other income expense net -2.40139M 0.71M -5.63823M -7.86423M -6.12437M
Discontinued operations - - - - -0.46264M
Net income from continuing ops -17.84429M -17.54843M -21.13353M -17.13873M -13.50447M
Net income applicable to common shares - - -20.82358M -16.76576M -15.86998M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 2.47M 10.79M 9.98M 18.56M 24.24M
Intangible assets - - 0.00000M 3.15M 7.05M
Earning assets - - - - -
Other current assets - - 0.40M 0.80M 0.83M
Total liab 11.10M 16.61M 18.02M 13.38M 10.41M
Total stockholder equity -8.62993M -5.15245M -7.40308M 5.84M 13.83M
Deferred long term liab - - - - -
Other current liab - 8.68M 1.12M 1.00M 0.66M
Common stock - - 103.69M 97.25M 84.51M
Capital stock 138.59M 123.29M 103.71M 97.44M 84.51M
Retained earnings -147.51272M -129.66842M -119.16892M -98.34534M -77.99790M
Other liab - - 4.30M 2.38M 2.51M
Good will - - - 3.15M 7.05M
Other assets - - 0.00000M 0.16M 0.56M
Cash 1.02M 0.70M 0.24M 1.89M 5.43M
Cash and equivalents - - - - -
Total current liabilities 10.83M 12.18M 13.33M 7.71M 6.13M
Current deferred revenue - - 0.66M 1.81M -4.28168M
Net debt 6.91M - 9.51M 2.47M 0.58M
Short term debt - - 9.37M 2.38M 4.24M
Short long term debt 7.93M - - 2.10M 4.69M
Short long term debt total - - 9.75M 4.35M 6.02M
Other stockholder equity - - 0.21M 0.00000M -6.51409M
Property plant equipment - - 7.45M 9.70M 7.14M
Total current assets 2.03M 2.74M 2.53M 6.46M 9.48M
Long term investments - 1.33M - 0.16M -
Net tangible assets - - -7.40308M 6.23M 6.79M
Short term investments - - - - -
Net receivables 0.07M 0.14M 0.53M 1.94M 2.35M
Long term debt - - - - 0.00000M
Inventory 0.13M 0.88M 1.36M 1.84M 0.87M
Accounts payable 1.81M 0.96M 2.19M 2.52M 1.22M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 8.08M 6.93M 7.32M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - -7.45309M -12.10018M -14.75427M
Deferred long term asset charges - - - - -
Non current assets total 0.44M 8.05M 7.45M 12.10M 14.75M
Capital lease obligations 0.36M 1.04M 0.58M 2.29M 1.98M
Long term debt total - - 0.38M 2.14M 1.77M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 0.21M -0.14012M 0.05M -2.44329M 0.30M
Change to liabilities - - 0.19M 1.63M -0.81997M
Total cashflows from investing activities 0.21M -0.14012M 0.61M -2.44329M -1.49378M
Net borrowings -0.20000M - 6.96M -0.26301M 5.49M
Total cash from financing activities 9.39M 14.87M 9.73M 9.74M 17.05M
Change to operating activities - - - - -
Net income -17.84429M -17.53060M -20.82358M -20.34744M -15.86998M
Change in cash 0.32M 0.46M -1.64653M -3.54689M 3.56M
Begin period cash flow 0.70M 0.24M 1.89M 5.43M 1.87M
End period cash flow 1.02M 0.70M 0.24M 1.89M 5.43M
Total cash from operating activities - - -11.98517M -12.15822M -11.98961M
Issuance of capital stock 10.40M 15.70M 2.70M 10.76M 12.76M
Depreciation - - 0.75M 0.41M 0.64M
Other cashflows from investing activities 0.21M - 0.80M 1.58M 2.45M
Dividends paid - - 9.62M 9.24M 16.10M
Change to inventory - - 0.48M -0.96536M -0.47021M
Change to account receivables - - 1.41M 1.29M -2.22031M
Sale purchase of stock - -0.59677M -0.31784M -0.76406M -1.20265M
Other cashflows from financing activities -0.80678M -0.23868M 14.45M 0.62M 12.45M
Change to netincome - - 6.02M 5.94M 6.90M
Capital expenditures 0.00223M 0.14M 0.19M 2.69M 3.33M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - - 2.07M 1.96M -3.51049M
Stock based compensation - - 2.66M 0.64M 1.65M
Other non cash items - - 5.45M 4.67M 11.54M
Free cash flow -9.28186M -14.40173M -12.17505M -14.85132M -15.31672M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RGT
Argent Biopharma Ltd		 -0.001 2.27% 0.04 - 14.37 10.87 9.85 28.01 -1.6171
AFP
Aft Pharmaceuticals Ltd		 - -% 3.00 23.08 19.88 1.35 3.81 1.72 13.67
VLS
Vita Life Sciences Ltd		 -0.02 0.80% 2.48 13.89 42.73 1.46 2.42 1.24 6.53
SNT
Syntara Ltd		 -0.001 3.33% 0.03 - 20.45 6.32 4.62 6.32 -2.1607
MVP
Medical Developments International Ltd		 0.005 1.23% 0.41 - 166.67 1.14 0.83 0.75 11.48

Reports Covered

Stock Research & News

View All

Profile

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound treatment. The company has collaborated with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.

Argent Biopharma Ltd

295 Rokeby Road, Subiaco, WA, Australia, 6008

Key Executives

Name Title Year Born
Mr. Roby Reuven Zomer Co-Founder, CEO, MD & Executive Director 1980
Mr. Tom Cairns Chief Accounting Officer NA
Ms. Yifat Steuer Deputy CEO & COO NA
Ms. Nicole Ann Godresse Global Chief Sales Officer NA
Mr. Amir Polak Chief Pharmaceutical Development Officer NA
Ms. Sabina Suljakovic Head of the Quality Assurance Department NA
Dr. Nadya Lisovoder Chief Medical Officer NA
Ms. Sasha Friedman Deputy CEO NA
Yair Tal Chief Information Security Officer NA
Mr. Robert Clements Chief Commercial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.